drugset / Trial / NCT07012005

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

NCT07012005

Phase 1 Completed 14 enrolled Shionogi
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of BPN14770 in participants with severe renal impairment and those with normal renal function.

Timeline

Start
2025-08-25
Primary completion
2025-12-15
Completion
2025-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject zatolmilast Small molecule Oral